Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
D Capodanno, R Mehran, M Valgimigli… - Nature Reviews …, 2018 - nature.com
In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …
Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
Objective To evaluate the efficacy and safety of standard term (12 months) or long term (> 12
months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after …
months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after …
Editor's choice–management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery …
AR Naylor, JB Ricco, GJ De Borst, S Debus… - European Journal of …, 2018 - ejves.com
AR Naylor a, J.-B. Ricco a, GJ de Borst a, S. Debus a, J. de Haro a, A. Halliday a, G.
Hamilton a, J. Kakisis a, S. Kakkos a, S. Lepidi a, HS Markus a, DJ McCabe a, J. Roy a, H …
Hamilton a, J. Kakisis a, S. Kakkos a, S. Lepidi a, HS Markus a, DJ McCabe a, J. Roy a, H …
Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE …
J Rodés-Cabau, JB Masson, RC Welsh… - JACC: Cardiovascular …, 2017 - jacc.org
Objectives: The aim of this study was to compare aspirin plus clopidogrel with aspirin alone
as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the …
as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the …
Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome: still sacrosanct or is reappraisal warranted?
Four decades have passed since the first trial suggesting the efficacy of aspirin in the
secondary prevention of myocardial infarction. Further trials, collectively summarized by the …
secondary prevention of myocardial infarction. Further trials, collectively summarized by the …
Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation
F Maes, E Stabile, GP Ussia, C Tamburino… - The American Journal of …, 2018 - Elsevier
To compare dual antiplatelet therapy (DAPT) versus single antiplatelet therapy (SAPT) as
antithrombotic treatment after transcatheter aortic valve implantation (TAVI) for the …
antithrombotic treatment after transcatheter aortic valve implantation (TAVI) for the …
Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy
Dual antiplatelet therapy (DAPT) has represented for decades the cornerstone of treatment
for the prevention of ischemic complications, including stent thrombosis, in patients …
for the prevention of ischemic complications, including stent thrombosis, in patients …
Association of sex with outcomes in patients undergoing percutaneous coronary intervention: a subgroup analysis of the GLOBAL LEADERS randomized clinical trial
P Chichareon, R Modolo, L Kerkmeijer… - JAMA …, 2020 - jamanetwork.com
Importance Women experience worse ischemic and bleeding outcomes after percutaneous
coronary intervention (PCI). Objectives To assess the association of sex with patient …
coronary intervention (PCI). Objectives To assess the association of sex with patient …
The factors influencing the efficiency of drug-coated balloons
Z Cao, J Li, Z Fang, Y Feierkaiti, X Zheng… - Frontiers in …, 2022 - frontiersin.org
The drug-coated balloon (DCB) is an emerging percutaneous coronary intervention (PCI)
device that delivers drugs to diseased vessels to decrease the rate of vascular stenosis …
device that delivers drugs to diseased vessels to decrease the rate of vascular stenosis …
[HTML][HTML] Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes …
S Masuda, T Muramatsu, Y Ishibashi, K Kozuma… - …, 2023 - ncbi.nlm.nih.gov
Abstract The Acetyl Salicylic Elimination Trial (ASET) Japan pilot study is a multicentre,
single-arm, open-label, proof-of-concept study with a stopping rule based on the occurrence …
single-arm, open-label, proof-of-concept study with a stopping rule based on the occurrence …